Evidence map›Paper›PMID 33804070›Full record

ArticleCurrent oncology (Toronto, Ont.)2021

Circulating miR-618 Has Prognostic Significance in Patients with Metastatic Colon Cancer.

Maria Radanova, Galya Mihaylova, Zhasmina Mihaylova, Desislava Ivanova, Oskan Tasinov, Neshe Nazifova-Tasinova, Pavel Pavlov, Milko Mirchev, Nikolay Conev, Ivan Donev

Open access · goldAbstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. mirSNPs as Potential Colorectal Cancer Biomarkers: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer.Journal of experimental & clinical cancer research : CR · 2022
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Maria RadanovaDepartment of Biochemistry, Molecular Medicine and Nutrigenomics, Medical University of Varna, 9000 Varna, Bulgaria.
Galya MihaylovaDepartment of Biochemistry, Molecular Medicine and Nutrigenomics, Medical University of Varna, 9000 Varna, Bulgaria.
Zhasmina MihaylovaClinic of Medical Oncology, Military Medical Academy, 1000 Sofia, Bulgaria.
Desislava IvanovaDepartment of Biochemistry, Molecular Medicine and Nutrigenomics, Medical University of Varna, 9000 Varna, Bulgaria.ORCID 0000-0001-8617-1043
Oskan TasinovDepartment of Biochemistry, Molecular Medicine and Nutrigenomics, Medical University of Varna, 9000 Varna, Bulgaria.ORCID 0000-0001-7268-3937
Neshe Nazifova-TasinovaDepartment of Biochemistry, Molecular Medicine and Nutrigenomics, Medical University of Varna, 9000 Varna, Bulgaria.
Pavel PavlovDepartment of General and Clinical Pathology, Forensic Medicine and Deontology, Medical University of Varna, 9000 Varna, Bulgaria.
Milko MirchevSecond Department of Internal Diseases, Medical University of Varna, 9000 Varna, Bulgaria.
Nikolay ConevDepartment of Oncology, Medical University of Varna, 9000 Varna, Bulgaria.
Ivan DonevClinic of Medical Oncology, Hospital Nadezhda, 1000 Sofia, Bulgaria.
Medical University of Varna · BGMilitary Medical Academy · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study evaluated the prognostic role of circulating miRNA-618 in patients with metastatic colon cancer (mCC) and whether miR-618 gene rs2682818 single nucleotide polymorphisms (SNP) are associated with colon cancer susceptibility and expression levels of mature miR-618. In total, 104 patients with mCC before starting the chemotherapy were investigated. The expression status of circulating miR-618 in mCC was evaluated by quantitative PCR. TaqMan PCR assay was used for rs2682818 SNP genotyping. miR-618 was overexpressed in serum of mCC patients. Patients with high and intermediate expression of miR-618 had a significantly longer mean overall survival (OS) of 21 months than patients with low expression-16 months. In addition, multivariate Cox regression analysis confirmed the association between high/intermediate levels of miRNA-618 and longer OS, HR = 0.51, 95% CI: 0.30-0.86,

Indexed as

Colonic NeoplasmsMicroRNAsGenetic Predisposition to DiseaseHumansPolymorphism, Single NucleotidePrognosisMicroRNAsMIRN618 microRNA, humanmetastatic colon cancermiR-618rs2682818

Identifiers

PMID33804070
PMCPMC8025826
OpenAlexW3139035671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.